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currently engaged in a number of patent law-
suits over sequencing technology, including 
one involving noninvasive prenatal genetic 
diagnostics for Down syndrome. But the com-
pany—with >$400 million in quarterly revenues 
and almost 400% growth in the past five years—
has mostly steered clear of patenting genes or 
methods of testing specific disorders. Rather, 
it has focused on its sequencing platform. As 
a consequence, it is constantly attempting to 
better—and outsell—its rivals.
These examples suggest that the genetics diag-
nostic marketplace is moving in two directions. 
The first, like GeneDx, is ‘commodities sequenc-
ing’ in which companies—armed with advanced 
and faster technologies developed elsewhere—
sequence genes or test for genetic disorders, 
picking up market share at ever-decreasing rates. 
Patent protection contributes little, if anything, 
to commodities-type sequencing, and consumer 
attraction is largely based on reputation, brand-
ing, cost and insurance coverage.
The other path, illustrated by Illumina, is 
to patent technology rather than genes—the 
hardware and software behind running the 
sequencers once patients’ samples come in the 
door. Because advancing sequencing costs a 
great deal in upfront engineering—and is easily 
copied—sequencing companies, like Illumina, 
have largely relied on their patent estate to 
police competitors. But they have also mostly 
forgone patenting disease-specific applications 
of their products. The goal is pure innovation: 
faster, more accurate and cheaper sequencing 
per nucleotide.
Myriad’s current market position, however, 
captures neither of these streams. It has not, 
despite its patent losses, come to terms with 
single-gene sequencing as a commodities busi-
ness. Nor has it developed its own sequencing 
platform, relying instead on the old-school Sanger 
method. The purchase of Crescendo suggests 
again that Myriad is attempting to corner a single 
diagnostic market on shaky IP. In sum, litigation 
and ever-evolving technological and business 
landscapes are killing monopoly-priced, single-
gene sequencing. As neither a commodities 
sequencer nor a sequencing innovator, Myriad 
stands alone as the last IP-forward, single-gene 
company in a multigene, multiplex world. 
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the surrounding genome. However, the Court 
upheld Myriad’s claims on BRCA1 and BRCA2 
cDNA on the grounds that such molecules were 
not naturally occurring.
Following the ruling, several companies 
immediately started offering tests for mutations 
in BRCA1/2; Myriad promptly sued them for 
patent infringement. In March, a Utah federal 
court denied Myriad a preliminary injunction 
that would have stopped its competitors from 
selling diagnostic tests, accusing Myriad of 
thwarting advancements in the field.
Critics of the company expected a death rattle. 
But Myriad remains very much alive. Although 
its initial patents expire in 2016, market inertia 
still provided $613 million in annual revenue 
to the company last year (a 23% increase from 
2012). Indeed, Myriad has been busy expand-
ing its footprint; it has stepped up its companion 
diagnostic program, and the recent $270-million 
purchase of Crescendo Biosciences signals a 
move away from gene-based to protein-based 
diagnostics. Yet Myriad has also continued to 
stock its patent portfolio, licensing almost a 
dozen university patents on methods of cancer 
screening, similar to those invalidated by the US 
Court of Appeals for the Federal Circuit.
Meanwhile, the diagnostics landscape has 
dramatically changed. Several companies 
(InVitae, Ambry and Counsyl) offer multiplex, 
whole-exome and whole-genome sequencing 
for comparable prices. But two companies stand 
out in comparison: GeneDx and Illumina.
GeneDx, founded in 2000 and one of Myriad’s 
litigation adversaries, specializes in rare-gene 
diagnostics. Today, it offers diagnostic sequencing 
for hundreds of disorders, as well as limited mul-
tigene panel and whole-exome screening, using 
mostly next-generation sequencing technology, at 
approximately half of Myriad’s per-gene cost. Its 
parent company, Bio-Reference Laboratories, has 
reported about $700 million in annual revenues, 
with much of that from GeneDx. GeneDx also 
has good relationships with all commercial insur-
ers and Medicare. In contrast to Myriad, GeneDx 
does not rely on gene or diagnostic patents it uses 
in testing, and even filed an amicus brief against 
Myriad in its Supreme Court case. Rather, many 
of GeneDx’s testing protocols come from freely 
available, publicly funded research—‘open source’ 
genetic testing.
Illumina, meanwhile, has developed a strong 
IP portfolio and enforced it aggressively. It is 
Myriad Genetics began in 1991 as a small University of Utah startup interested in 
the then-novel arena of diagnostic genetic test-
ing. After winning a highly publicized race to 
sequence the BRCA1 and BRCA2 breast cancer 
genes, the company obtained patents on the 
gene sequences and methods of using them to 
determine cancer risk. The patents were broad 
and interlocking, covering BRCA genomic 
DNA, cDNA, methods of diagnosis and systems 
detecting mutations. Myriad also filed for diag-
nostic ‘toolbox’ patents, including two claiming 
any DNA primer or probe sharing 15 nucleo-
tides with the wild-type BRCA1 or BRCA2 it 
first sequenced. These patents became the heart 
of the company.
Since then, the decision to aggressively assert 
this intellectual property (IP) has become 
synonymous with the Myriad name. Unlike 
other diagnostic companies that pursued 
cross-licensing opportunities, Myriad was 
voraciously litigious, sending cease-and-desist 
letters to competitors, clinicians and research-
ers. It also developed a proprietary database of 
rare mutations in the two genes—“variants of 
uncertain significance”—that it closed to out-
side researchers in 2004. Access to healthcare 
was another flashpoint. It charged as much as 
$4,000 for its flagship test BRCAnalysis—not 
uniformly covered by health insurers—where 
similar, unpatented tests cost as little as $100. 
Civil libertarians, bioethicists and advocacy 
groups argued that this squeezed patients seek-
ing BRCA sequencing into a single, high-priced 
option. From a business perspective, however, 
Myriad’s strategy paid off handsomely. Between 
1997 and 2013, Myriad sold around one million 
tests and generated $2 billion in revenue, 80% of 
it coming from its BRCAnalysis product.
In 2009, these business practices led a group 
of patients, physicians and public interest 
groups to challenge Myriad’s patents in court. In 
response, the US Court of Appeals invalidated 
Myriad’s patents’ method claims in 2012. And 
in June 2013, the US Supreme Court invalidated 
several claims on the genes themselves. The 
Court reasoned that isolated BRCA fragments 
were unpatentable “products of nature,” even 
though they were “isolated and purified” from 
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coMMentary case  study
Myriad stands alone
Jacob S Sherkow & Christopher Scott
Myriad took no prisoners on its way to the top of the molecular diagnostics field. That strategy is unlikely to endure.
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